Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.

MLA

Graybill, Whitney S., et al. “Predictors of Long-Term Progression-Free Survival in Patients with Ovarian Cancer Treated with Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study.” International Journal of Gynecological Cancer, vol. 34, no. 7, July 2024, pp. 1041–50. EBSCOhost, https://doi.org/10.1136/ijgc-2024-005356.

APA

Graybill, W. S., Búrdalo, B. P., O’Malley, D. M., Vergote, I., Monk, B. J., Auranen, A., Copeland, L. J., Sabbatini, R., Herzog, T. J., Follana, P., Pothuri, B., Braicu, E. I., McCormick, C., Yubero, A., Moore, R. G., Vuylsteke, P., Raaschou-Jensen, N., York, W., Hartman, J., & González-Martín, A. (2024). Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study. International Journal of Gynecological Cancer, 34(7), 1041–1050. https://doi.org/10.1136/ijgc-2024-005356

Chicago

Graybill, Whitney S., Beatriz Pardo Búrdalo, David M. O’Malley, Ignace Vergote, Bradley J. Monk, Annika Auranen, Larry J. Copeland, et al. 2024. “Predictors of Long-Term Progression-Free Survival in Patients with Ovarian Cancer Treated with Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study.” International Journal of Gynecological Cancer 34 (7): 1041–50. doi:10.1136/ijgc-2024-005356.